Editing Oivi

{{DISPLAYTITLE:Oivi}}
{{Infobox company
| name = Oivi AS
| org_number = 920032265
| founded = 2017-11-25
| employees = 7
| address = Norway
| industry = 62.200 – Computer consultancy activities
| website = https://www.oivi.co
| nht_category = Startup
| description = Oivi develops a smart fundus camera for diabetic retinopathy screening. Enables early detection of diabetic retinopathy at point-of-care, reaching high-risk patients wherever they are located. Uses custom-built optics and robotics with AI. Addresses the global diabetes epidemic — 500M adults with diabetes, 1 in 3 develop diabetic retinopathy.
| notes = No disclosed revenue or funding. 7 employees. Waitlist mode for product launch. International support from EU and India innovation leaders.
| related_companies = [[Picterus]], [[Diagnostrix]], [[NordicDx]], [[Norway Health Tech]]
| categories = Norway Health Tech, Startups, Medical Devices, Diagnostics, Eye Health, AI
| sources = https://www.oivi.co (Wayback Machine); https://data.brreg.no/enhetsregisteret/api/enheter/920032265
}}

== About ==

Oivi AS is a Norwegian medical technology company developing smart eye screening solutions. Founded in 2017 with 7 employees, the company focuses on enabling early detection of diabetic retinopathy.

== Technology ==

=== Oivi Fundus Camera ===

Oivi has developed a system combining:
* Custom-built optics
* Robotics
* Artificial intelligence
* Cloud connectivity

The Oivi camera enables screening for diabetic retinopathy at the point of care — in primary care centres, diabetes clinics, pharmacies, or eye hospitals — rather than requiring referral to a specialist ophthalmologist.

== Clinical Need ==

* 500 million adults worldwide suffer from diabetes
* Projected 51% increase in diabetes by 2045
* 1 in 3 people with diabetes develop diabetic retinopathy
* Diabetic retinopathy is a leading cause of preventable blindness
* Early detection enables treatment before vision loss occurs

== Value Proposition ==

* Early detection of diabetic retinopathy reduces preventable blindness
* Point-of-care screening reaches high-risk patients in primary care settings
* Rapid diagnosis shortens time-to-treatment
* Reduces costs for patients and healthcare systems

== Market Position ==

Oivi competes in the diabetic retinopathy screening market with companies including Remidio, EYENZA, and others. The company's approach using custom-built optics and robotics represents a hardware-intensive approach to AI-based screening.

== References ==
<references/>

[[Category:Norway Health Tech]]
[[Category:Startups]]
[[Category:Medical Devices]]
[[Category:Diagnostics]]
[[Category:Eye Health]]
[[Category:AI]]